54969-29-8

Basic information

• Product Name: 2-Piperazinecarboxaldehyde, 1,4-bis(phenylmethyl)-
• CAS NO: 54969-29-8
• Molecular Formula: C19H22N2O
• Molecular Weight: 294.396
• Mol File: 54969-29-8.mol

Chemical Properties

• CAS DataBase Reference: 2-Piperazinecarboxaldehyde, 1,4-bis(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Piperazinecarboxaldehyde, 1,4-bis(phenylmethyl)-(54969-29-8)
• EPA Substance Registry System: 2-Piperazinecarboxaldehyde, 1,4-bis(phenylmethyl)-(54969-29-8)

Safety Data

• Hazardous Substances Data: 54969-29-8(Hazardous Substances Data)

Upstream product

• 140-28-3 N,N'-Dibenzylethylenediamine 
• 72351-59-8 ethyl 1,4-dibenzylpiperazin-2-carboxylate 

Downstream Products

• 259808-15-6 1,4-dibenzyl-2-(2-methyl-2-propenyl)piperazine 
• 1310452-84-6 1,4-dibenzyl-2-(difluoromethyl)piperazine 
• 272786-64-8 Unifiram 
• 117810-52-3 2,3,4,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-6-one 
• 141856-04-4 2-Benzylhexahydropyrrolo<1,2-a>pyrazin-6(2H)-one 
• 259808-17-8 1-[(5-chloro-1-phenylsulfonylindol-2-yl)sulfonyl]-3-(2-methylpropyl)piperazine 

Relevant articles and documents

Rapid access to 1-benzyl 2-substituted piperazines: Application to the synthesis of 1-benzyl-2-difluoromethyl-piperazine

A rapid and efficient synthesis of 1-benzyl-2-difluoromethyl-piperazine is herein described. The new pathway has the advantage of avoiding orthogonal protection at the two piperazine nitrogen atoms; therefore it is suitable for access to several 1-benzyl

QUINOLINE DERIVATIVES AS SMO INHIBITORS

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss

The present invention relates to methods for treating a subject suffering from tinnitus, hearing loss, or tinnitus and hearing loss comprising administering to the subject an effective amount of an NK1 receptor antagonist alone, or in combination with an

Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites

Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fXa inhibitors with excellent potency in anti-fXa and anticoagulant assays. The optimized compounds 73b and 75b showed sub to one digit micromolar anticoagulant activity (PTCT2). Particularly, anti-fXa activity was detected in plasma of rats orally administered with 1 mg/kg of compound 75b.

Novel aminoglycoside derivatives

Novel aminoglycoside derivatives and their salts containing 2-deoxystreptamine moiety, of which the 1-amino group is acylated by a group represented by the formula: STR1 (wherein R is 4 to 6 membered heterocyclic group containing 1 to 2 nitrogen atoms whi